NCT00068484View on ClinicalTrials.gov

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

February 28, 2006

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

topotecan hydrochloride

Given IV

DRUG

bortezomib

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

06520-8032

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00068484 - A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies | Biotech Hunter | Biotech Hunter